Education
About Us
Working with TipRanks
Follow Us
Metsera, Inc. (MTSR)
:MTSR
MTSR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.30 - $32.81
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.12M
Market Cap
$2.51B
Enterprise ValueN/A
Total Cash (Recent Filing)$352.45M
Total Debt (Recent Filing)$9.80M
Price to Earnings (P/E)―
Beta1.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding105,050,220
10 Day Avg. Volume783,622
30 Day Avg. Volume1,120,513
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$47.00Price Target Upside67.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Metsera, Inc. News
PremiumCompany Announcements
Metsera, Inc. Appoints New Board Member and Legal Officer
PremiumCompany Announcements
Metsera, Inc. Approves 2024 Executive Cash Bonuses
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityMetsera is well-funded with enough cash to last through 2026, providing stability as they advance their clinical trials.
Market EntryThe fully biased, potentially monthly, subQ lead asset, GLP1RA MET-097i, is poised to secure MTSR a stake in the growing obesity market.
Pipeline DevelopmentMTSR's differentiated ultra-long-acting NuSH analog pipeline is seen as a highly promising multi-billion opportunity.
Bears Say
Clinical Trial RisksAdvancing clinical trials always carries the risk of unforeseen delays or failures, which could impact Metsera's progress.
Market CompetitionMetsera's entry into the obesity market might face challenges due to competition from established players.
---
Options Prices
Currently, No data available
---
Ownership Overview
30.74% Insiders
0.20% Mutual Funds
<0.01% Other Institutional Investors
67.78% Public Companies and
Individual Investors
MTSR FAQ
What was Metsera, Inc.’s price range in the past 12 months?
Metsera, Inc. lowest stock price was $12.30 and its highest was $32.81 in the past 12 months.
What is Metsera, Inc.’s market cap?
Metsera, Inc.’s market cap is $2.51B.
When is Metsera, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Metsera, Inc.’s earnings last quarter?
Metsera, Inc. released its earnings results on Mar 26, 2025. The company reported -$3.52 earnings per share for the quarter, missing the consensus estimate of -$0.61 by -$2.91.
Is Metsera, Inc. overvalued?
According to Wall Street analysts Metsera, Inc.’s price is currently Undervalued.
Does Metsera, Inc. pay dividends?
Metsera, Inc. does not currently pay dividends.
What is Metsera, Inc.’s EPS estimate?
Metsera, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Metsera, Inc. have?
Metsera, Inc. has 105,050,220 shares outstanding.
What happened to Metsera, Inc.’s price movement after its last earnings report?
Metsera, Inc. reported an EPS of -$3.52 in its last earnings report, missing expectations of -$0.61. Following the earnings report the stock price went down -3.601%.
Which hedge fund is a major shareholder of Metsera, Inc.?
Currently, no hedge funds are holding shares in MTSR
---
Metsera, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.00 (67.20% Upside)
$47.00 (67.20% Upside)
Blogger Sentiment
Bullish
MTSR Sentiment 70%
Sector Average 68%
Sector Average 68%
Insider Transactions
Bought Shares
Worth $94.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
172.88%
Trailing 12-Months
Company Description
Metsera, Inc.
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
---
MTSR Stock 12 Month Forecast
Average Price Target
$47.00
▲(67.20% Upside)
Technical Analysis
---